ADAM17: An Emerging Therapeutic Target for Lung Cancer

The molecular, cellular and pathophysiological roles of iRhom pseudoproteases

(2019) Iqbal Dulloo et al.   Open Biology

ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer

(2019) Mohamed I Saad et al.   EMBO Molecular Medicine

Commensal Microbiota Promote Lung Cancer Development via γδ T Cells

(2019) Chengcheng Jin et al.   CELL

SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors

(2019) Hengyu Lu et al.   MOLECULAR CANCER THERAPEUTICS

The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis

(2019) Mohamed I Saad et al.   CARCINOGENESIS

Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase

(2018) Dana M. Gwinn et al.   CANCER CELL

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

(2018) Chiara Ambrogio et al.   CELL

Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma

(2018) Jens Kohler et al.   CURRENT MEDICINAL CHEMISTRY

ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling

(2018) Stefanie Schmidt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

(2018) Sara Mainardi et al.   NATURE MEDICINE

An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo

(2018) Koichi Tomoshige et al.   ONCOGENE

Differential Effector Engagement by Oncogenic KRAS

(2018) Tina L. Yuan et al.   Cell Reports

SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models

(2018) Carmine Fedele et al.   Cancer Discovery

Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo

(2017) Jie Ye et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma

(2017) Wenzheng Fang et al.   JOURNAL OF SURGICAL RESEARCH

Potential efficacy of interleukin-1β inhibition in lung cancer

(2017) Brendan J Jenkins   LANCET

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

(2017) Paul M Ridker et al.   LANCET

Emerging functions of the EGFR in cancer

(2017) Sara Sigismund et al.   Molecular Oncology

The role of IL-6 in host defence against infections: immunobiology and clinical implications

(2017) Stefan Rose-John et al.   Nature Reviews Rheumatology

Phosphorylation of iRhom2 Controls Stimulated Proteolytic Shedding by the Metalloprotease ADAM17/TACE

(2017) Miguel Cavadas et al.   Cell Reports

Phosphorylation of iRhom2 at the plasma membrane controls mammalian TACE-dependent inflammatory and growth factor signalling

(2017) Adam Graham Grieve et al.   eLife

Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

(2017) R. C. Newton et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Targeting of the IL-6 Trans-Signaling/Mechanistic Target of Rapamycin Complex 1 Axis in Pulmonary Emphysema

(2016) Saleela M. Ruwanpura et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Stimulated release and functional activity of surface expressed metalloproteinase ADAM17 in exosomes

(2016) Esther Groth et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis

(2016) G. D. Brooks et al.   CANCER RESEARCH

Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer

(2016) A. Sharma et al.   CLINICAL CANCER RESEARCH

Novel therapeutic targets on the horizon for lung cancer

(2016) Wan-Ling Tan et al.   LANCET ONCOLOGY

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

(2016) Jonathan M. L. Ostrem et al.   NATURE REVIEWS DRUG DISCOVERY

Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma

(2016) A Miller et al.   ONCOGENE

Harnessing the natural inhibitory domain to control TNFα Converting Enzyme (TACE) activity in vivo

(2016) Eitan Wong et al.   Scientific Reports

Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ibα Retention During Ex Vivo Generation of Human Induced Pluripotent Stem Cell-Derived Platelets

(2016) Shinji Hirata et al.   Stem Cells Translational Medicine

Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics

(2016) Carmen Capone et al.   eLife

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells

(2015) F Caiazza et al.   BRITISH JOURNAL OF CANCER

Global Cancer Incidence and Mortality Rates and Trends--An Update

(2015) L. A. Torre et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma

(2015) Ming Cai et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Allergen-induced IL-6 trans-signaling activates γδ T cells to promote type 2 and type 17 airway inflammation

(2015) Md Ashik Ullah et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles

(2015) Neele Schumacher et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex

(2015) Marine Lacroix et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

(2015) Chee-Seng Tan et al.   LANCET ONCOLOGY

Lineage factors and differentiation states in lung cancer progression

(2015) W K C Cheung et al.   ONCOGENE

A biosensor for the activity of the “sheddase” TACE (ADAM17) reveals novel and cell type–specific mechanisms of TACE activation

(2015) Douglas A. Chapnick et al.   Science Signaling

A biosensor for the activity of the “sheddase” TACE (ADAM17) reveals novel and cell type–specific mechanisms of TACE activation

(2015) Douglas A. Chapnick et al.   Science Signaling

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

(2015) Q. J. Wang et al.   Cancer Immunology Research

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

(2015) Jiabei He et al.   Scientific Reports

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

Senescence-associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding

(2014) Timo Effenberger et al.   FASEB JOURNAL

DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model

(2014) T-Y Weng et al.   GENE THERAPY

Targeting the Sheddase Activity of ADAM17 by an Anti-ADAM17 Antibody D1(A12) Inhibits Head and Neck Squamous Cell Carcinoma Cell Proliferation and Motility via Blockage of Bradykinin Induced HERs Transactivation

(2014) Yanchao Huang et al.   International Journal of Biological Sciences

A Disintegrin and Metalloprotease 17 Dynamic Interaction Sequence, the Sweet Tooth for the Human Interleukin 6 Receptor

(2014) Stefan Düsterhöft et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer

(2014) XIAOHONG LV et al.   Molecular Medicine Reports

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis

(2014) A Miller et al.   ONCOGENE

Opposing role of Notch1 and Notch2 in a KrasG12D-driven murine non-small cell lung cancer model

(2014) A Baumgart et al.   ONCOGENE

T helper 17 cells play a critical pathogenic role in lung cancer

(2014) S. H. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Receptor Tyrosine Kinases: Legacy of the First Two Decades

(2014) J. Schlessinger   Cold Spring Harbor Perspectives in Biology

Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation

(2013) Yonka Christova et al.   EMBO REPORTS

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Thirdhand Tobacco Smoke: A Tobacco-Specific Lung Carcinogen on Surfaces in Smokers' Homes

(2013) J. L. Thomas et al.   NICOTINE & TOBACCO RESEARCH

ADAM17, shedding, TACE as therapeutic targets

(2013) Stefan Rose-John   PHARMACOLOGICAL RESEARCH

Systemic Overexpression of TNFα-converting Enzyme Does Not Lead to Enhanced Shedding Activity In Vivo

(2013) Masaki Yoda et al.   PLoS One

Regulated ADAM17-dependent EGF family ligand release by substrate-selecting signaling pathways

(2013) M. Dang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities

(2013) Jürgen Scheller et al.   SEMINARS IN IMMUNOLOGY

ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival

(2013) Shuang-Shuang Ni et al.   TUMOR BIOLOGY

EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

(2012) Christine M. Ardito et al.   CANCER CELL

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

(2012) Haoqiang Ying et al.   CELL

Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer

(2012) M. Terashima et al.   CLINICAL CANCER RESEARCH

KRAS Mutations in Lung Cancer

(2012) Niki Karachaliou et al.   Clinical Lung Cancer

Lung endothelial ADAM17 regulates the acute inflammatory response to lipopolysaccharide

(2012) Daniela Dreymueller et al.   EMBO Molecular Medicine

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-1 Stimulates ADAM17 through a Mechanism Independent of its Cytoplasmic Domain or Phosphorylation at Threonine 735

(2012) Katherine C. Hall et al.   PLoS One

Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo

(2012) Frances M. Richards et al.   PLoS One

Tumor Necrosis Factor Signaling Requires iRhom2 to Promote Trafficking and Activation of TACE

(2012) C. Adrain et al.   SCIENCE

TACE Activation by MAPK-Mediated Regulation of Cell Surface Dimerization and TIMP3 Association

(2012) P. Xu et al.   Science Signaling

The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer

(2011) Q Sheng et al.   BRITISH JOURNAL OF CANCER

Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression

(2011) Michel DuPage et al.   CANCER CELL

The sheddase activity of ADAM17/TACE is regulated by the tetraspanin CD9

(2011) Maria Dolores Gutiérrez-López et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis

(2011) R. Zaynagetdinov et al.   JOURNAL OF IMMUNOLOGY

ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway

(2011) Ping Lin et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Research Opportunities Related to Establishing Standards for Tobacco Products Under the Family Smoking Prevention and Tobacco Control Act

(2011) S. S. Hecht   NICOTINE & TOBACCO RESEARCH

TACE/ADAM-17 Phosphorylation by PKC-Epsilon Mediates Premalignant Changes in Tobacco Smoke-Exposed Lung Cells

(2011) Hassan Lemjabbar-Alaoui et al.   PLoS One

Leukocyte ADAM17 Regulates Acute Pulmonary Inflammation

(2011) Patrick G. Arndt et al.   PLoS One

ADAM17: a molecular switch to control inflammation and tissue regeneration

(2011) Jürgen Scheller et al.   TRENDS IN IMMUNOLOGY

Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression

(2010) J-W Kornfeld et al.   BRITISH JOURNAL OF CANCER

ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation

(2010) Xuguang Zheng et al.   CANCER BIOLOGY & THERAPY

Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer Patients.

(2010) S. Friedman et al.   CANCER RESEARCH

ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non-Small Cell Lung Cancer

(2010) A. Baumgart et al.   CANCER RESEARCH

Pathological Neovascularization Is Reduced by Inactivation of ADAM17 in Endothelial Cells but Not in Pericytes

(2010) Gisela Weskamp et al.   CIRCULATION RESEARCH

ADAM-17: the enzyme that does it all

(2010) Monika Gooz   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

(2010) Synne Wedén et al.   INTERNATIONAL JOURNAL OF CANCER

ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site

(2010) S. M. Le Gall et al.   JOURNAL OF CELL SCIENCE

Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice

(2010) Athena Chalaris et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Direct Activation of TACE-Mediated Ectodomain Shedding by p38 MAP Kinase Regulates EGF Receptor-Dependent Cell Proliferation

(2010) Pinglong Xu et al.   MOLECULAR CELL

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway

(2010) S Eliasz et al.   ONCOGENE

Comparative Functional Genomics Analysis of NNK Tobacco-Carcinogen Induced Lung Adenocarcinoma Development in Gprc5a-Knockout Mice

(2010) Junya Fujimoto et al.   PLoS One

MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands

(2010) K. Brandl et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10

(2009) Cristina I. Caescu et al.   BIOCHEMICAL JOURNAL

Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion

(2009) A. Brill et al.   CARDIOVASCULAR RESEARCH

Regulation of Mature ADAM17 by Redox Agents for L-Selectin Shedding

(2009) Y. Wang et al.   JOURNAL OF IMMUNOLOGY

Selective Use of ADAM10 and ADAM17 in Activation of Notch1 Signaling

(2009) E. C. Bozkulak et al.   MOLECULAR AND CELLULAR BIOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Expression of ADAMs (“a disintegrin and metalloprotease”) in the human lung

(2009) Antoon Dijkstra et al.   VIRCHOWS ARCHIV

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Alterations of Cellular Redox State During NNK-Induced Malignant Transformation and Resistance to Radiation

(2008) Yusuke Demizu et al.   ANTIOXIDANTS & REDOX SIGNALING

Two conformational states of Ras GTPase exhibit differential GTP-binding kinetics

(2008) Jingling Liao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor

(2008) L. Witters et al.   CANCER RESEARCH

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

(2008) R. M. Giusti et al.   CLINICAL CANCER RESEARCH

EGFR family: Structure physiology signalling and therapeutic targets†

(2008) Antony W. Burgess   GROWTH FACTORS

The molecular logic of Notch signaling - a structural and biochemical perspective

(2008) W. R. Gordon et al.   JOURNAL OF CELL SCIENCE

Structural Determinants of the ADAM Inhibition by TIMP-3: Crystal Structure of the TACE-N-TIMP-3 Complex

(2008) Magdalena Wisniewska et al.   JOURNAL OF MOLECULAR BIOLOGY

Common origins of lung cancer and COPD

(2008) A McGarry Houghton et al.   NATURE MEDICINE

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rational targeting of Notch signaling in cancer

(2008) P Rizzo et al.   ONCOGENE